Effect of transcranial direct current stimulation on sports performance for two profiles of athletes (power and endurance) (COMPETE): a protocol for a randomised, crossover, double blind, controlled exploratory trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
03 Jun 2020
Historique:
received: 27 09 2019
accepted: 14 05 2020
entrez: 5 6 2020
pubmed: 5 6 2020
medline: 16 2 2021
Statut: epublish

Résumé

Transcranial direct current stimulation (tDCS) is promising for improving motor and cognitive performance. Nevertheless, its mechanisms of action are unclear and need to be better characterised according to the stimulated brain area and the type of exercise performed. This is a double-blind crossover study, organised into two parts: the first is to assess the effects of tDCS on explosive performance (jump task) and the second is to assess the effects on endurance performance (cycling time trial task). Participants, who are recreationally active or athletes (parkour practitioners, cyclists), will receive two active tDCS sessions (over the left dorsolateral prefrontal cortex and right motor cortex) and one sham tDCS session (part A), or two sequences (one active and one sham) of two daily tDCS sessions over 5 days (part B). Motor and cognitive performance will be compared before and after tDCS sessions (part A), and before and after the first session, after the last session and at day 12 and day 30 of each tDCS sequence (part B). This study investigates the acute and repeated effects of tDCS on the motor and cognitive performance of healthy subjects. It will try to evaluate if tDCS could be considered as a neuroenhancement technology according to the physical task investigated (endurance versus explosive). ClinicalTrials.gov, NCT03937115. Registered on 3 May 2019; retrospectively registered.

Sections du résumé

BACKGROUND BACKGROUND
Transcranial direct current stimulation (tDCS) is promising for improving motor and cognitive performance. Nevertheless, its mechanisms of action are unclear and need to be better characterised according to the stimulated brain area and the type of exercise performed.
METHODS/DESIGN METHODS
This is a double-blind crossover study, organised into two parts: the first is to assess the effects of tDCS on explosive performance (jump task) and the second is to assess the effects on endurance performance (cycling time trial task). Participants, who are recreationally active or athletes (parkour practitioners, cyclists), will receive two active tDCS sessions (over the left dorsolateral prefrontal cortex and right motor cortex) and one sham tDCS session (part A), or two sequences (one active and one sham) of two daily tDCS sessions over 5 days (part B). Motor and cognitive performance will be compared before and after tDCS sessions (part A), and before and after the first session, after the last session and at day 12 and day 30 of each tDCS sequence (part B).
DISCUSSION CONCLUSIONS
This study investigates the acute and repeated effects of tDCS on the motor and cognitive performance of healthy subjects. It will try to evaluate if tDCS could be considered as a neuroenhancement technology according to the physical task investigated (endurance versus explosive).
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov, NCT03937115. Registered on 3 May 2019; retrospectively registered.

Identifiants

pubmed: 32493462
doi: 10.1186/s13063-020-04412-0
pii: 10.1186/s13063-020-04412-0
pmc: PMC7268738
doi:

Banques de données

ClinicalTrials.gov
['NCT03937115']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

461

Références

J Neurosci. 2011 Jul 20;31(29):10712-20
pubmed: 21775614
J Exp Psychol Gen. 1999 Mar;128(1):78-87
pubmed: 10100392
Neuroscience. 2016 May 13;322:94-103
pubmed: 26892298
J Electromyogr Kinesiol. 2000 Oct;10(5):361-74
pubmed: 11018445
Appl Physiol Nutr Metab. 2013 Jul;38(7):734-9
pubmed: 23980731
Front Hum Neurosci. 2019 Apr 05;13:103
pubmed: 31024275
J Strength Cond Res. 2020 Jan;34(1):97-103
pubmed: 28426515
Eur J Neurosci. 2007 Jul;26(1):242-9
pubmed: 17614951
Brain Stimul. 2016 Nov - Dec;9(6):842-849
pubmed: 27567471
Science. 2003 Nov 14;302(5648):1181-5
pubmed: 14615530
Neuroscience. 2015 Jun 25;297:219-30
pubmed: 25849613
Physiol Rep. 2014 Dec 11;2(12):
pubmed: 25501438
J Alzheimers Dis. 2014;42(4):1203-8
pubmed: 25024318
Adv Exp Med Biol. 2013;789:73-79
pubmed: 23852479
Front Hum Neurosci. 2017 May 10;11:243
pubmed: 28539880
Biol Psychiatry. 2003 Sep 1;54(5):573-83
pubmed: 12946886
Eur J Appl Physiol. 2008 Jan;102(2):153-63
pubmed: 17882449
Sports Med. 2013 Jun;43(6):437-49
pubmed: 23456490
Science. 2000 Jun 9;288(5472):1835-8
pubmed: 10846167
Behav Anal. 2016 Aug 19;39(2):293-304
pubmed: 31976983
Neuroscience. 2016 Dec 17;339:363-375
pubmed: 27751960
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Am J Sports Med. 2017 May;45(6):1405-1412
pubmed: 28288281
J Exp Psychol Appl. 2002 Jun;8(2):75-84
pubmed: 12075692
PLoS One. 2009 Aug 12;4(8):e6598
pubmed: 19672310
Clin Exp Pharmacol Physiol. 2006 Apr;33(4):400-5
pubmed: 16620309
J Physiol. 2005 Oct 1;568(Pt 1):291-303
pubmed: 16002441
J Physiol. 2000 Sep 15;527 Pt 3:633-9
pubmed: 10990547
Prog Brain Res. 2018;240:317-339
pubmed: 30390837
Can J Psychiatry. 2000 Mar;45(2):156-65
pubmed: 10742875
Brain Stimul. 2019 May - Jun;12(3):593-605
pubmed: 30630690
J Appl Physiol (1985). 2016 Feb 15;120(4):464-6
pubmed: 26404617
J Neurophysiol. 2012 Mar;107(6):1649-54
pubmed: 22190624
Front Syst Neurosci. 2014 Sep 04;8:159
pubmed: 25237299
Neurology. 2001 Nov 27;57(10):1899-901
pubmed: 11723286
Eur J Appl Physiol. 2018 Jul;118(7):1361-1371
pubmed: 29679247
J Physiol. 2011 Jul 15;589(Pt 14):3533-44
pubmed: 21606110
Sports Med. 2014 Sep;44(9):1319-20
pubmed: 24809249

Auteurs

Yohan Grandperrin (Y)

Service de Psychiatrie de l'Adulte, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France. ygrandperrin@chu-besancon.fr.
Laboratoire de Neurosciences Intégratives et Cliniques EA481, Université de Bourgogne Franche-Comté, 19 rue Ambroise Paré, 25000, Besançon, France. ygrandperrin@chu-besancon.fr.

Sidney Grosprêtre (S)

Laboratoire Culture, Sport, Santé, Société EA 4660, Université de Bourgogne Franche -Comté, UPFR Sports, 25000, Besançon, France.

Magali Nicolier (M)

Service de Psychiatrie de l'Adulte, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.
Laboratoire de Neurosciences Intégratives et Cliniques EA481, Université de Bourgogne Franche-Comté, 19 rue Ambroise Paré, 25000, Besançon, France.
Centre d'Investigation Clinique, INSERM CIC 1431, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.

Philippe Gimenez (P)

Laboratoire Culture, Sport, Santé, Société EA 4660, Université de Bourgogne Franche -Comté, UPFR Sports, 25000, Besançon, France.

Chrystelle Vidal (C)

Centre d'Investigation Clinique, INSERM CIC 1431, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.

Emmanuel Haffen (E)

Service de Psychiatrie de l'Adulte, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.
Laboratoire de Neurosciences Intégratives et Cliniques EA481, Université de Bourgogne Franche-Comté, 19 rue Ambroise Paré, 25000, Besançon, France.
Centre d'Investigation Clinique, INSERM CIC 1431, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.
Centre Expert Dépression Résistante FondaMental, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.

Djamila Bennabi (D)

Service de Psychiatrie de l'Adulte, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.
Laboratoire de Neurosciences Intégratives et Cliniques EA481, Université de Bourgogne Franche-Comté, 19 rue Ambroise Paré, 25000, Besançon, France.
Centre d'Investigation Clinique, INSERM CIC 1431, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.
Centre Expert Dépression Résistante FondaMental, Centre Hospitalier Universitaire de Besançon, 25030, Besançon Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH